Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
- 1 July 2011
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 22 (7), 1682-1690
- https://doi.org/10.1093/annonc/mdq644
Abstract
The purpose of this study was to confirm sunitinib activity in alveolar soft part sarcoma (ASPS) and to report on new insights into the molecular bases thereof. From July 2007, nine patients with progressive metastatic ASPS received sunitinib 37.5 mg/day, within a named use program. Cryopreserved material was available for five naive patients, among whom three received sunitinib. Immunofluorescence (IF)/confocal microscopy, biochemical, and molecular/cytogenetic analyses were carried out, complemented by antiproliferative and activation assays in a short-term culture derived from one case. All patients were eligible for response. Best RECIST response was partial response in five cases, stable disease in three, and progression in one. The median progression-free survival was 17 months. Positron emission tomography results were consistent. Two cases of interval progressions were recorded. Antiproliferative assays and biochemistry on short-term culture showed that sunitinib is able to markedly impair ASPS cells growth and switch-off PDGFRB. IF/confocal microscopy demonstrated coexpression and physical association between PDGFRB/vascular endothelial growth factor receptor 2 (VEGFR2) and RET/VEGFR2 in ASPS cells, which was validated by biochemistry. PDGFRB, RET, and MET ligand-dependent activation was confirmed. We confirm the clinical efficacy of sunitinib in ASPS, mediated by PDGFRB, VEGFR2, and RET, which are all expressed in tumor cells. A direct antitumor effect was shown in a short-term cell culture.Keywords
Funding Information
- Italian Ministry of Health
This publication has 36 references indexed in Scilit:
- Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single InstitutionAnnals of Surgical Oncology, 2010
- Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarrayHistopathology, 2009
- Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumorsJournal of Clinical Oncology, 2009
- Gene expression profiling of alveolar soft-part sarcoma (ASPS)BMC Cancer, 2009
- Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part SarcomaClinical Cancer Research, 2007
- Chemotherapy in alveolar soft part sarcomas: What do we know?European Journal of Cancer, 2003
- Alveolar Soft Part Sarcoma in Japan: Multi-Institutional Study of 57 Patients from the Japanese Musculoskeletal Oncology GroupOncology, 2003
- Alveolar soft part sarcomaCancer, 2001
- The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25Oncogene, 2001
- Alveolar soft-part sarcoma. A clinico-pathologic study of half a centuryCancer, 1989